HomeCorMatrix® Cardiovascular Inc.

CorMatrix® Cardiovascular Inc.

CorMatrix Cardiovascular Receives European Community and U.S. Patent Claim Allowances for Polymer Drug Delivery Prostheses

The European and U.S. Patent allowances will further enhance CorMatrix's growing synthetic polymer and ECM (Extracellular Matrix) delivery platforms, which, in addition to PGS, includes poly(urethane urea), polylactide (PLA), poly(e-caprolactone) (PCL) and polyglycolide (PLGA) compositions and structures.

CorMatrix® Cardiovascular, Inc. Receives FDA Approval to Expand and Enroll 20 Additional Patients in the Adult Arm of its Early Feasibility  IDE study of the Cor® TRICUSPID ECM® Valve for Pediatric and Adult Patients

The Cor® TRICUSPID ECM® valve has been successfully implanted in the 11th patient enrolled in the expansion by Dr. Marc Gerdisch, Chief of Cardiothoracic Surgery at Franciscan Health Heart Center in Indianapolis, Indiana & principal investigator for the adult component of the study.